Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK

Biochemical Pharmacology

Volumn 116, Issue , 2016, Pages 39-50

  Zhou, Hongyu ^a,b   Shang, Chaowei ^b   Wang, Min ^a   Shen, Tao ^b   Kong, Lingmei ^a   Yu, Chunlei ^a,c   Ye, Zhennan ^a   Luo, Yan ^b   Liu, Lei ^b   Li, Yan ^a   Huang, Shile ^b  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

AMPK; Ciclopirox; mTOR; Raptor; TSC2

Indexed keywords

ADENOSINE TRIPHOSPHATE; CICLOPIROXOLAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; S6 KINASE; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN RECEPTOR; TUBERIN; ANTINEOPLASTIC AGENT; CICLOPIROX; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRIDONE DERIVATIVE; RECOMBINANT PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA CELL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; GERMFREE ANIMAL; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; RANDOMIZATION; RHABDOMYOSARCOMA; TUMOR CELL LINE; TUMOR VOLUME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MICE, NUDE; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIDONES; RANDOM ALLOCATION; RECOMBINANT PROTEINS; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84983749117     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.07.005     Document Type: Article

References (55)

1. [1] Abrams, B.B., Hanel, H., Hoehler, T., Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin. Dermatol. 9 (1991), 471–477.
2. [2] Gupta, A.K., Ciclopirox: an overview. Int. J. Dermatol. 40 (2001), 305–310.
3. [3] Leem, S.H., Park, J.E., Kim, I.S., Chae, J.Y., Sugino, A., Sunwoo, Y., The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol. Cells 15 (2003), 55–61.
4. [4] Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Korting, H.C., Hube, B., Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob. Agents Chemother. 47 (2003), 1805–1817.
5. [5] Eberhard, Y., McDermott, S.P., Wang, X., Gronda, M., Venugopal, A., Wood, T.E., et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114 (2009), 3064–3073.
6. [6] Minden, M.D., Hogge, D.E., Weir, S.J., Kasper, J., Webster, D.A., Patton, L., et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am. J. Hematol. 89 (2014), 363–368.
7. [7] Zhou, H., Shen, T., Luo, Y., Liu, L., Chen, W., Xu, B., et al. The antitumor activity of the fungicide ciclopirox. Int. J. Cancer 127 (2010), 2467–2477.
8. [8] Kim, Y., Schmidt, M., Endo, T., Lu, D., Carson, D., Schmidt-Wolf, I.G., Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 25 (2011), 887–893.
9. [9] Zhou, H., Shen, T., Shang, C., Luo, Y., Liu, L., Yan, J., et al. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget 5 (2014), 10140–10150.
10. [10] Clement, P.M., Hanauske-Abel, H.M., Wolff, E.C., Kleinman, H.K., Park, M.H., The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int. J. Cancer 100 (2002), 491–498.
11. [11] Linden, T., Katschinski, D.M., Eckhardt, K., Scheid, A., Pagel, H., Wenger, R.H., The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. Faseb J. 17 (2003), 761–763.
12. [12] Luo, Y., Zhou, H., Liu, L., Shen, T., Chen, W., Xu, B., et al. The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene 30 (2011), 2098–2107.
13. [13] Sen, S., Hassane, D.C., Corbett, C., Becker, M.W., Jordan, C.T., Guzman, M.L., Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Exp. Hematol. 41 (2013), 799–807, e794.
14. [14] Laplante, M., Sabatini, D.M., MTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
15. [15] Sun, S.Y., MTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 340 (2013), 1–8.
16. [16] Zhang, Y.J., Duan, Y., Zheng, X.F., Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 16 (2011), 325–331.
17. [17] Inoki, K., Kim, J., Guan, K.L., AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 52 (2012), 381–400.
18. [18] Sarbassov, D.D., Guertin, D.A., Ali, S.M., Sabatini, D.M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005), 1098–1101.
19. [19] Garcia-Martinez, J.M., Alessi, D.R., MTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416 (2008), 375–385.
20. [20] Gulhati, P., Bowen, K.A., Liu, J., Stevens, P.D., Rychahou, P.G., Chen, M., et al. MTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 71 (2011), 3246–3256.
21. [21] Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6 (2004), 1122–1128.
22. [22] Liu, L., Chen, L., Chung, J., Huang, S., Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 27 (2008), 4998–5010.
23. [23] Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004), 1296–1302.
24. [24] Huang, S., Houghton, P.J., Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3 (2003), 371–377.
25. [25] Rodrik-Outmezguine, V.S., Chandarlapaty, S., Pagano, N.C., Poulikakos, P.I., Scaltriti, M., Moskatel, E., et al. MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1 (2011), 248–259.
26. [26] Huang, Z., Wu, Y., Zhou, X., Qian, J., Zhu, W., Shu, Y., et al. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncol. 11 (2015), 1687–1699.
27. [27] Inoki, K., Zhu, T., Guan, K.L., TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003), 577–590.
28. [28] Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13 (2003), 2004–2008.
29. [29] Hardie, D.G., AMPK–sensing energy while talking to other signaling pathways. Cell Metab. 20 (2014), 939–952.
30. [30] Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C., Blenis, J., Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13 (2003), 1259–1268.
31. [31] Garami, A., Zwartkruis, F.J., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11 (2003), 1457–1466.
32. [32] Inoki, K., Li, Y., Xu, T., Guan, K.L., Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003), 1829–1834.
33. [33] Zhang, Y., Gao, X., Saucedo, L.J., Ru, B., Edgar, B.A., Pan, D., Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5 (2003), 578–581.
34. [34] Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30 (2008), 214–226.
35. [35] Urano, J., Sato, T., Matsuo, T., Otsubo, Y., Yamamoto, M., Tamanoi, F., Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 3514–3519.
36. [36] Yin, W., Cheepala, S., Roberts, J.N., Syson-Chan, K., DiGiovanni, J., Clifford, J.L., Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol. Cancer, 5, 2006, 15.
37. [37] Kim, Y.D., Park, K.G., Lee, Y.S., Park, Y.Y., Kim, D.K., Nedumaran, B., et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57 (2008), 306–314.
38. [38] Liu, L., Li, F., Cardelli, J.A., Martin, K.A., Blenis, J., Huang, S., Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25 (2006), 7029–7040.
39. [39] Wan, X., Shen, N., Mendoza, A., Khanna, C., Helman, L.J., CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8 (2006), 394–401.
40. [40] Hashemolhosseini, S., Nagamine, Y., Morley, S.J., Desrivieres, S., Mercep, L., Ferrari, S., Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. 273 (1998), 14424–14429.
41. [41] Gao, N., Flynn, D.C., Zhang, Z., Zhong, X.S., Walker, V., Liu, K.J., et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. 287 (2004), C281–291.
42. [42] Tirado, O.M., Mateo-Lozano, S., Notario, V., Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 24 (2005), 3348–3357.
43. [43] Stromberg, T., Dimberg, A., Hammarberg, A., Carlson, K., Osterborg, A., Nilsson, K., et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103 (2004), 3138–3147.
44. [44] Feng, Z., Fan, X., Jiao, Y., Ban, K., Mammalian target of rapamycin regulates expression of beta-catenin in hepatocellular carcinoma. Hum. Pathol. 42 (2011), 659–668.
45. [45] Luo, Y., Liu, L., Rogers, D., Su, W., Odaka, Y., Zhou, H., et al. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia 14 (2012), 228–237.
46. [46] Huang, S., Shu, L., Easton, J., Harwood, F.C., Germain, G.S., Ichijo, H., et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J. Biol. Chem. 279 (2004), 36490–36496.
47. [47] Schneider, A., Younis, R.H., Gutkind, J.S., Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 10 (2008), 1295–1302.
48. [48] Roy, A., Volgin, D.V., Baby, S.M., Mokashi, A., Kubin, L., Lahiri, S., Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci. Lett. 363 (2004), 229–232.
49. [49] Li, Y., Wang, X., Yue, P., Tao, H., Ramalingam, S.S., Owonikoko, T.K., et al. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. J. Biol. Chem. 288 (2013), 13215–13224.
50. [50] Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006), 159–168.
51. [51] Shi, Y., Yan, H., Frost, P., Gera, J., Lichtenstein, A., Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4 (2005), 1533–1540.
52. [52] Sun, S.Y., Rosenberg, L.M., Wang, X., Zhou, Z., Yue, P., Fu, H., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005), 7052–7058.
53. [53] O'Reilly, K.E., Rojo, F., She, Q.B., Solit, D., Mills, G.B., Smith, D., et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006), 1500–1508.
54. [54] Hsu, P.P., Kang, S.A., Rameseder, J., Zhang, Y., Ottina, K.A., Lim, D., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332 (2011), 1317–1322.
55. [55] Yu, Y., Yoon, S.O., Poulogiannis, G., Yang, Q., Ma, X.M., Villen, J., et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332 (2011), 1322–1326.